Runner who injured ankle evacuated by boat from Lake District location
Penrith Mountain Rescue Team were called to respond to the incident on June 1 by the runner who requested assistance following an injury sustained on the lakeshore path beneath Hallin Fell.
Patterdale Mountain Rescue launched their rescue boat which allowed team members from both organisations to transport the runner across Ullswater to Watermillock.
A spokesperson for Penrith MRT said: "Patterdale Mountain Rescue Team asked us to respond to this incident for them as they had an event on at their base.
"A runner in an organised event had sustained an ankle injury on the lakeshore path beneath Hallin Fell and requested mountain rescue assistance.
"The Patterdale team launched their rescue boat, and 2 team members along with a Penrith team member went to the scene to assess and stabilise the casualty.
"A further 8 Penrith team members were transported from Howtown via the boat direct to the scene to evacuate the casualty to the boat.
"The casualty was taken across Ullswater to Watermillock and transferred to the waiting ambulance.
"Our thanks to Patterdale for sending the boat as this removed an awkward carry along the lake shore path to Howtown."
The rescue involved ten Penrith team members and two from Patterdale - it took just over four hours.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
Yahoo
13 hours ago
- Yahoo
'I never once thought I needed to get out'
Jack Butland insists he never considered seeking an escape route this summer and Rangers remains the club "where I want to be". The former England goalkeeper lost his Ibrox starting spot to Liam Kelly during the final months of last term under interim boss Barry Ferguson. But Butland, 32, was give the gloves by new head coach Russell Martin for the season-opening first-leg win over Panathinaikos in Champions League qualifying last week and is determined to build on that impressive performance. "Has it been smooth sailing, my time at the club? Not for me personally, for all of us, no, it's not been quite as successful as we'd like it to have been," Butland told Sky Sports. "I never lost that, I didn't walk away from the season thinking, although some people like to try and make those stories up, that that's the end of it. "I was very determined that I will determine how my career goes here. "Obviously things can be taken out of your hands at times, but I was very adamant in the summer that regardless of what happens, what managerial changes, ownership changes, that I was going to come in and be the best version of myself and at least give myself the opportunity to have control of what happens next. "I hope I've managed to do that. I certainly feel fit and sharp and positive and looking forward to the season ahead at a club where I want to be. "I never once looked away from it and thought I need a change or I need to get out. "I need to keep my head up, stick my chest out and get on with it. That's the plan."
Yahoo
13 hours ago
- Yahoo
🎥 England celebrate EURO 2025 triumph with London bus parade
The EURO 2025 champions are back home and celebrating with their fans. It's been a packed 48 hours for the England squad having touched down on Monday following their win over Spain for a reception at 10 Downing Street. But the party isn't over with the Lionesses now on an open top bus parade down The Mall in central London and heading towards Buckingham Palace. Are some of the best clips from the parade so far ... Early vibes on the bus ... Sunday's goalscorer has her say ... It came home ... Heading down The Mall ... What a way to toast the queens of Europe. 📸 Alex Pantling - 2025 Getty Images
